Navigation Links
Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity
Date:9/1/2009

he clinic in 2010."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

Intercept's lead compound, INT-747, is a modified human bile acid and first-in-class FXR agonist that is currently in Phase II testing. Clinical proof of concept was recently demonstrated in a Phase II, placebo-controlled trial of INT-747 in type 2 diabetics with fatty liver disease. Based on these results, the company plans to advance INT-747 in a Phase IIb trial in patients with nonalcoholic steatohepatitis (NASH) in 2010. INT-747 is completing two additional Phase II trials in patients with primary biliary cirrhosis, an autoimmune cholestatic liver disease and orphan indication. Results from the first of the two studies are expected in the fourth quarter of 2009.

INT-777 is a modified human bile acid and selective TGR5 agonist that is currently being assessed in IND-enabling studies.

For more information about Intercept, please go to www.interceptpharma.com; and for information about Intercept's lead investor, Genextra S.p.A., please go to www.genextra.it.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH
2. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Consortium publishes Phase II map of human genetic variation
5. The Lancet Publishes Vasogens ACCLAIM Results
6. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
7. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Springer publishes anthology with the Nanoethics Group
9. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
10. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
11. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
(Date:7/1/2015)... Wilmington, DE (PRWEB) , ... July 01, 2015 , ... ... to develop new ideas to lower the barriers to innovation in life sciences R&D. ... for up to two cash prizes of US$15,000 and a period of expert mentorship ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical ... new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. ... that will increase healthcare worker safety and reduce financial costs. , CTI Electronics ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... - Strengthened Balance Sheet and Advancing Products in 2008 - ... 11:00 a.m. Eastern Time -, BRANFORD, Conn., Jan. 31 ... financial results for the,fourth quarter and fiscal year ended December ... the fourth quarter of 2007,of $11.0 million, or $0.20 per ...
... (Euronext: AMT), a leader in the field of ... plan of rotation to appoint independent,directors to its ... Mr. Philippe van Holle, Head of Celgene Europe ... of shareholders. Mr. Van Holle is expected to,replace ...
... FRANCISCO, Calif., Jan. 30 Monogram,Biosciences, Inc., (Nasdaq: ... on Thursday, February 7, 2008 at 4:30 p.m. (Eastern ... discuss the outlook for 2008.,The call will be hosted ... To participate in the live teleconference, please call ...
Cached Biology Technology:CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 2CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 3CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 4CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 5CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 6CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 7Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board 2Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board 3Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call 2
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, a ... authentication solutions, today announced enhanced functionality of its ... solution.  The enhancements build on the native ... DigitalPersona Altus platform and provide expanded mobile ... In today,s environment of increasing cyber-attacks ...
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... developed a method to dramatically improve the longevity of ... motion of a single molecule as it travels through ... process called resonance energy transfer, which occurs when fluorescent ... will be reported at the 234th annual national American ...
... Staph Infections in Humans Including MRSA ... against Staphylococcus aureus, including methicillin-resistant strains, in mice ... in the August 2007 issue of the journal ... a highly flexible and potentially dangerous pathogen capable ...
... study in the August 21st issue of Current Biology, a ... evidence in support of the long-held notion that men and ... the researchers found that women really do prefer pinkor at ... we expected to find sex differences, we were surprised at ...
Cached Biology News:Clemson scientists shed light on molecules in living cells 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Girls prefer pink, or at least a redder shade of blue 2